Flamel's Strategy

By combining the Company's established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners.

The Company’s business model is to leverage its proprietary technology platforms through partnership agreements. This approach is a highly efficient way to develop a diversified portfolio of product opportunities while benefiting from the partner companies' comparative advantage in areas such as clinical development and regulatory affairs, as well as sales and marketing.

Flamel's Alliances

Flamel Technologies has currently partnerships with the following companies :

Company	Product/Description	Indications	Technology	Status
	Blood clotting factors	Hemophilia	MEDUSA	Undisclosed
	COREG CR	Cardiovascular diseases	MICROPUMP	Launched
	Undisclosed Marketed Protein	Undisclosed	MEDUSA	Undisclosed
	Undisclosed	Undisclosed	Undisclosed	Undisclosed
	Undisclosed Marketed Protein	Undisclosed	MEDUSA	Undisclosed

Flamel has other undisclosed partnerships.